Skip to content
Medical Health Aged Care

Free vaccine will protect NSW from deadly Meningococcal B: RACGP

Royal Australian College of GPs 2 mins read

The Royal Australian College of General Practitioners is calling on the New South Wales government to protect families by providing the life-saving Meningococcal B vaccine for at-risk groups.  

Meningococcal B is a rare but devastating disease, which can progress quickly and lead to death or disability. The RACGP is calling on the New South Wales government to make it free for key at-risk groups.  

To ensure more people in NSW are protected from the potentially deadly infection, the RACGP recommends free Meningococcal B vaccines for every child aged two and under and every teen aged 15 to 19-years-old.  

Stacey Chater and her family were left devastated in 2022 when Meningococcal B suddenly and rapidly claimed the life of her 23-year-old son Brayden. 

She said: “My son Brayden was the perfect example of the typical young Aussie bloke, he loved his family and his mates, he kept fit, and he was full of life.

“He had a fever and a sniffle one night and 24 hours later we were at the hospital being told he was gone. I can’t explain the shock and disbelief. Meningococcal B is so quick and aggressive and so hard to know that you have it. Our family has been struggling for two years, and my doctor has diagnosed me with PTSD.

“Like most people, I never knew that there was a strain of meningococcal that my children weren’t vaccinated against, I assumed that they were covered by the vaccines they received at school. 

“Financial burden is preventing Australians from being able to get the Meningococcal B vaccine. 

“This is a devastating, traumatic disease that can be prevented. No other family should have to go through the journey we have been on, access to free vaccines would be life changing for families in NSW.”  

RACGP NSW & ACT Chair Dr Rebekah Hoffman said: “We can dramatically reduce the deaths and disability related to Meningococcal B. Effective vaccines are available, now it is up to the government to ensure free access to all at-risk Australians.  

“Meningococcal B is rare, but deadly. Statistics show it kills 5 to 10% of patients and leaves 10 to 20% of survivors with brain damage, hearing loss or a learning disability. 

“This virus is most devastating for vulnerable kids and young people, and out-of-pocket costs shouldn’t prevent any parents in NSW from protecting their children.   

“Prevention is the best solution, and effective vaccines are one of the most important tools we have for keeping our people safe from deadly infections such as these.  

"In South Australia, the Meningococcal B vaccination program cut rates amongst children by 60%, and by 73% amongst adolescents. Queensland and the Northen Territory have also rolled out successful programs and it is time for NSW to match these commitments."

Meningitis Centre Australia CEO Karen said: “You cannot place a cost on a life or our children’s future. 86% of patients simply cannot afford this lifesaving Meningococcal B vaccination, the government can fix this, saving NSW children from death and lifelong disability.” 

~ENDS


About us:

The Royal Australian College of General Practitioners (RACGP) is the peak representative organisation for general practice, the backbone of Australia’s health system. We set the standards for general practice, facilitate lifelong learning for GPs, connect the general practice community, and advocate for better health and wellbeing for all Australians.

Visit www.racgp.org.au. To unsubscribe from RACGP media releases, click here.


Contact details:

John Ronan
Media Adviser

Ally Francis
Media Adviser

Stuart Winthrope
Media Officer

Contact: 03 8699 0992[email protected]

Follow us on Twitter: @RACGP and Facebook.

More from this category

  • Medical Health Aged Care, Research Development
  • 11/07/2025
  • 16:28
The Florey

Harnessing mRNA to prevent and slow Alzheimer’s disease

mRNA Victoria funds 2Floreyprojects to prevent and treat Alzheimer’s disease Key points mRNA Victoria has funded 2 Alzheimer’s disease research projects that could position Victoria as a leader in the development of mRNA-based therapies. Dr Abdel Belaidi will develop an mRNA-based system that crosses the blood-brain barrier and aims to slow or even halt disease progression. Dr Rebecca Nisbet will develop an mRNA vaccine that aims to prevent Alzheimer’s disease from developing. Florey researchers working at the cutting edge of dementia research have received funding from mRNA Victoria to develop treatments and a vaccine for Alzheimer’s disease. Since mRNA vaccines…

  • Medical Health Aged Care
  • 11/07/2025
  • 07:05
Royal Australian College of GPs

GPs urge Tasmanian families to get vaccinated against whooping cough and call for free shots to reduce barriers

The Royal Australian College of GPs (RACGP) is urging Tasmanian families to get vaccinated against pertussis, or ‘whooping cough’ and called on all parties and candidates running in the state election to commit to making the vaccination free for all patients. From 1 January 2024 to April 2025, 1238 whooping cough cases were notified in Tasmania, including 10 infants aged under six months. Most hospitalisations and deaths occur in this group, who are not old enough to have received all vaccine doses. More than 21,000 infections were recorded nationwide last year, compared to just 2450 in 2023, and the National…

  • Contains:
  • General News, Medical Health Aged Care
  • 11/07/2025
  • 07:00
La Trobe University

La Trobe researchers awarded $4.5 million in ARC Future Fellowships

LaTrobe University researchers have secured almost $4.5 million in Federal Government funding to further studies into areas such as immune cell development, Australian history and agriculture. Four researchers received an Australian Research Council (ARC) Future Fellowship 2025. The prestigious Future Fellowships support high quality research in areas of national and international benefit, including in national research priorities. Dr Lisa Mielke, from the School of Cancer Medicine, the La Trobe Institute of Molecular Science (LIMS) and the Olivia Newton-John Cancer Research Institute (ONJCRI), received $1.13 million to identify new molecules for future drug and vaccine development to improve gut health in…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.